Northern Trust
ADCT icon

Northern Trust’s ADC Therapeutics ADCT Stock Holding History

Northern Trust’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07M Buy
552,201
+114,650
+26% +$452K ﹤0.01% 2961
2025
Q4 		$1.54M Buy
437,551
+19,984
+5% +$81.1K ﹤0.01% 3142
2025
Q3 		$1.67M Sell
417,567
-9,319
-2% -$29.4K ﹤0.01% 3130
2025
Q2 		$1.14M Sell
426,886
-69,258
-14% -$146K ﹤0.01% 3310
2025
Q1 		$700K Buy
496,144
+19,951
+4% +$33.9K ﹤0.01% 3428
2024
Q4 		$948K Sell
476,193
-4,844
-1% -$12.7K ﹤0.01% 3418
2024
Q3 		$1.52M Buy
481,037
+458,023
+1,990% +$1.44M ﹤0.01% 3157
2024
Q2 		$72.7K Buy
+23,014
New +$91.5K ﹤0.01% 4125

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust's ADCT Position: Q1 2026 in Review

Northern Trust increased its ADC Therapeutics (ADCT) stake by 26% in Q1 2026, buying an estimated $452K and bringing the position to 552,201 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2961.

Northern Trust first reported a position in ADCT in Q2 2024 and has held it in 8 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Northern Trust held 552,201 shares of ADC Therapeutics worth $2.07M as of Q1 2026.
  • Northern Trust bought 114,650 ADC Therapeutics shares in Q1 2026, an estimated $452K.
  • ADC Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2961 holding.
  • Northern Trust first reported a position in ADC Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.